Prices from Twelve Data (may be delayed) — Hong Kong Stock Exchange tickers (e.g. “0700.HK”) instead use EODHD, the only free source found that covers HKEX. Fundamentals from SEC EDGAR (US filers only). Not investment advice — see the data sources appendix on each company page for full detail.
← Back to search

AstraZeneca PLC American Depositary Shares AZN

NASDAQ

$155.62

-2.35 (-1.49%)

A quick, factual read on the price trend and the underlying business — not a recommendation, and not a substitute for reading the numbers below yourself.

At a glance

Below 200DMASoft momentumNear 52-week lowModerate ROEUnavailableLower than marketHigh multiple

19

Technical strength

Trend, momentum, position vs averages

  • • Price is 15.7% below its 200-day moving average.
  • • 14-day RSI is 32.
  • • Sits at 15% of its 52-week range (0% = low, 100% = high).

68

Fundamental quality

Margins, returns, leverage, growth

  • • Gross margin is 82.0%.
  • • Return on equity is 16.1%.
  • • Revenue grew 3.3% year over year.

$157.95

Open

$157.97

Previous close

$212.71

52-week high

$145.80

52-week low

8,057,497

Volume

4,524,280

Avg. volume

$177.89

50-day avg.

+28%

Volatility (ann.)

Context

  • Trading 6.7% above its 52-week low, and closer to the bottom of its 52-week range.
  • Trading 12.5% below its 50-day average price, consistent with recent downward momentum.
  • Annualized price volatility over this period is about 28%, which is moderately volatile next to a typical broad-market stock (commonly ~15-25%).

About

AstraZeneca (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Yahoo Finance ↗SEC EDGAR filings ↗Wikipedia ↗

Fundamentals & valuation (FY2025, from SEC filings)

Core financials

$45.8bn

Revenue (latest FY)

+3.29%

Revenue growth (YoY)

$6.0bn

Net income (latest FY)

+81.95%

Gross margin

+17.88%

Operating margin

$3.81

EPS (diluted)

$5.8bn

Cash & equivalents

+13.01%

Net margin

+80.57%

EPS growth (YoY)

-$2.0bn

Working capital

$37.1bn

Shareholders' equity

$10.3bn

Operating cash flow

Valuation multiples

$155.62

Price

40.8x

P/E ratio

Growth & returns

+3.29%

Revenue growth (YoY)

+80.57%

EPS growth (YoY)

+16.09%

ROE

+5.73%

ROA

Credit metrics & WACC inputs

0.26

Beta (vs. S&P 500)

$5.8bn

Cash & equivalents

In the news

Want to go further?

Build your own investment report from this data — pick a report type, add your thesis, and export a PDF.